Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Assets (2021 - 2025)

Kiniksa Pharmaceuticals International's Assets history spans 5 years, with the latest figure at $763.6 million for Q4 2025.

  • For Q4 2025, Assets rose 31.54% year-over-year to $763.6 million; the TTM value through Dec 2025 reached $763.6 million, up 31.54%, while the annual FY2025 figure was $763.6 million, 31.54% up from the prior year.
  • Assets reached $763.6 million in Q4 2025 per KNSA's latest filing, up from $712.3 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $763.6 million in Q4 2025 to a low of $210.6 million in Q2 2022.
  • Average Assets over 5 years is $465.4 million, with a median of $483.7 million recorded in 2023.
  • Peak YoY movement for Assets: decreased 25.77% in 2022, then surged 130.0% in 2023.
  • A 5-year view of Assets shows it stood at $232.8 million in 2021, then skyrocketed by 97.45% to $459.7 million in 2022, then rose by 14.5% to $526.3 million in 2023, then grew by 10.3% to $580.6 million in 2024, then skyrocketed by 31.54% to $763.6 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Assets are $763.6 million (Q4 2025), $712.3 million (Q3 2025), and $661.2 million (Q2 2025).